卡塔尔波尔对血管生成和潜在机制的促进作用:基于网络药理学的研究
Jin-Rong Ni1, Qun-Hu Zhang1, Jie-Lin Deng1
1Department of Orthopedics, Jiangsu Province (Suqian) Hospital, Suqian, China.
Chemical biology & drug design
|August 12, 2024
概括
卡塔尔波尔是一种天然化合物,通过增加EGFR表达在人静脉内皮细胞中,促进血管形成 (血管生成). 这表明它有治疗血管疾病的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 卡塔尔波尔是一种虹膜糖化物,具有抗炎和神经保护性质.
- 调节血管生成对于治疗各种疾病至关重要.
- 了解catalpol的血管效应对于其治疗发展至关重要.
研究的目的:
- 为了研究catalpol对血管生成的影响.
- 阐明catalpol血管新生作用的潜在机制.
- 评估catalpol在血管相关疾病中的治疗潜力.
主要方法:
- 使用SwissTargetPrediction,GeneCards,DAVID和Cytoscape进行网络药理学分析.
- 在人静脉内皮细胞 (HUVEC) 的体外实验,包括CCK-8,血管新生,RT-qPCR和西部斑检测.
- 对目标基因,蛋白-蛋白相互作用和基因本体学丰富的分析.
主要成果:
- 确定了312个catalpol目标和823个血管生成目标,其中56个是共同的目标.
- 突出的枢纽基因 (AKT1,EGFR,STAT3,MAPK3,CASP3) 在脂质/动脉样硬化和EGFR通路中富含.
- 卡塔尔波尔证明了HUVEC活力,迁移和血管生成的剂量依赖性增加,上调EGFR表达.
结论:
- 卡塔尔波尔通过上调EGFR和相关蛋白质来促进HUVEC血管生成.
- 对于catalpol的益血管性作用来说,EGFR信号是必不可少的.
- 卡塔尔波尔显示出作为治疗血管疾病的治疗剂的希望.
相关概念视频
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164


